Helus Pharma Inc. (HELP)
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Helus Pharma Inc. Common Stock
NASDAQ:HELPHealthcare · Medical - Pharmaceuticals
+3.24%$9.25
Prev close$8.96+3.01%Open$9.23+0.22%Now$9.25
Mkt Cap$675.89M
Float50.07M
O/S73.07M
VOL513K sh
$ Vol$4.71M
RVOL0.34×
Inst Own42.4%
SI6.0%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 9.23 | 9.43 | 8.75 | 9.24 | 512,696 |
| Nov 6, 2026 | 8.63 | 9.18 | 8.53 | 8.96 | 1,210,026 |
| Nov 5, 2026 | 8.55 | 8.74 | 8.20 | 8.39 | 1,445,951 |
| Nov 4, 2026 | 9.03 | 9.33 | 8.55 | 8.68 | 1,253,269 |
| Nov 3, 2026 | 9.11 | 9.57 | 8.94 | 9.03 | 1,237,070 |
| Nov 2, 2026 | 10.80 | 10.85 | 8.32 | 8.80 | 3,888,895 |
| Oct 30, 2026 | 10.53 | 10.98 | 10.42 | 10.60 | 1,146,328 |
| Oct 29, 2026 | 10.91 | 11.30 | 10.51 | 10.71 | 790,340 |
| Oct 28, 2026 | 10.63 | 10.93 | 10.34 | 10.91 | 664,549 |
| Oct 27, 2026 | 10.22 | 10.77 | 9.71 | 10.52 | 1,527,250 |
| Oct 26, 2026 | 10.08 | 10.90 | 10.06 | 10.36 | 1,033,739 |
| Oct 23, 2026 | 10.50 | 10.75 | 9.87 | 10.19 | 1,894,833 |
| Oct 22, 2026 | 10.60 | 11.44 | 10.42 | 10.50 | 1,916,014 |
| Oct 21, 2026 | 11.10 | 11.66 | 10.75 | 10.78 | 936,358 |
| Oct 20, 2026 | 10.75 | 11.74 | 10.67 | 10.94 | 2,365,698 |
| Oct 19, 2026 | 10.53 | 10.92 | 10.33 | 10.69 | 976,407 |
| Oct 16, 2026 | 11.06 | 11.06 | 10.38 | 10.55 | 1,313,790 |
| Oct 15, 2026 | 10.30 | 11.15 | 10.13 | 11.05 | 1,534,458 |
| Oct 14, 2026 | 10.36 | 10.47 | 10.19 | 10.38 | 1,054,852 |
| Oct 13, 2026 | 11.31 | 11.31 | 9.97 | 10.50 | 3,174,976 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not availableRatings Distribution
BUY3
HOLD0
SELL0
TOTAL3
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 So Eric H. L. | Director | Grant/Award | 248.0K | -- | Sep 30, 2026 |
 Glavine Paul | Chief Growth Officer | Grant/Award | 248.0K | -- | Sep 30, 2026 |
 Cavers Greg | Chief Financial Officer | Purchase | 3.0K | $38.7K | Sep 29, 2026 |
Shareholders
42.4%
Institutional
(109)
0.7%
Insiderⓘ
(7)
19.1%
5%+ Owners
(3)
37.9%
Unattributed (incl. retail)ⓘ
Institutional42.4%
Insider0.7%
5%+ Beneficial19.1%
Unattributed (incl. retail)37.9%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
PETER DAVID RANDS · may incl. warrants· filed Nov 2023 | 16.6M | 4.3% as filed | 13G |
Venrock Healthcare Capital Partners III, L.P. · may incl. warrants· reaffirmed 13F Aug 2026 | 5.1M | 7.0% | 13G |
So Eric H. L. · joint filing· may incl. warrants· filed Sep 2026 | 4.4M | 6.1% | 13D |
Glavine Paul · joint filing· may incl. warrants· filed Sep 2026 | 4.4M | 6.0% | 13D |
Venrock Adviser, LLC | 3.9M | 5.3% | 13F |
Adage Capital Management, L.P. · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 3.3M | 4.5% | 13G |
ORBIMED ADVISORS LLC | 3.3M | 4.5% | 13F |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.1M | 4.2% | 13F |
MILLENNIUM MANAGEMENT LLC | 2.6M | 3.6% | 13F |
Millennium Management LLC · also on 13F· may incl. warrants· filed Mar 2026 | 2.4M | 3.3% | 13G |
Sources: 13F, Form 4, 13D/13GO/S: 73.1M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders
Insiders
- So Eric H. L.Director
- Glavine PaulChief Growth Officer
- Cavers GregChief Financial Officer
- Halstead MichaelChief Executive Officer
- Lewis-Hall Freda CDirector
- Firestone TheresaDirector
- Inamdar AmirDirector
- Lawson MarkDirector
- Hoskins EricDirector
About
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds.
Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Key Metrics
Market Cap$675.89M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership42.36%
based on 73.07M shares outstanding
SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeNASDAQ
Country
CA
CAIPO DateJan 5, 2026
Shares Outstanding73.07M
Authorized Shares
Float50.07M
52-Week Range
$3.76$14.35
$9.25(52nd percentile)
Volume
Average Daily Volume1.53M
512.70K today vs 1.53M avg(-67%)
30d Avg
1.53M
60d Avg
1.61M
90d Avg
1.61M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...